Tag: conversion

Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation.

KOŠICE, Slovakia, July 26, 2025 (GLOBE NEWSWIRE) -- Remittix (RTX), a crypto payments project focused on practical financial utility, has officially announced the Q3 2025 launch of its beta wallet featuring Solana and Ethereum integration. The news follows strong momentum in its presale phase, which has now exceeded $17.3 million in contributions and 573 million tokens sold.

KOŠICE, Slovakia, July 26, 2025 (GLOBE NEWSWIRE) -- Remittix (RTX), a crypto payments platform aiming to simplify cross-border and freelance transactions, has confirmed the Q3 2025 launch of its beta wallet, alongside newly announced integration with the Solana blockchain. These developments mark key milestones in Remittix’s roadmap toward enabling fast, low-cost, and user-friendly crypto-to-fiat payments.

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-12 (the “Reverse Stock Split”). The Company’s common stock is expected to commence trading on a split-adjusted basis when the NYSE American market opens on August 5, 2025 under the existing symbol of “CLDI.” The new CUSIP number for the Company’s common stock following the Reverse Stock Split will be 320703 408.

Descriptif du programme de rachat d’actions autorisé par l’Assemblée Générale Mixte du 23 mai 2025 

CALGARY, Alberta, July 24, 2025 (GLOBE NEWSWIRE) -- Athabasca Oil Corporation (TSX: ATH) (“Athabasca” or the “Company”) is pleased to report its second quarter results marked by strong operational performance, consistent financial results and execution on return of capital commitments. With low corporate break-evens, differentiated long-life assets and a pristine balance sheet, the Company is well positioned to advance its strategic priorities.